stockfy wrote: We have the haters who bought above $10 a few years ago when CPH hit $17 in 2015 - 2016 and sold at a big loss lately. So now they come here and make inaccurate remarks or post lies. Understandable why they are so bitter. I'm really sorry that you bought CPH at such a high valuation.
But debt-free CPH is at $0.90 now. Dirt-cheap and debt-free. We also have those who can't read the press releases or are unable to understand a balance sheet.
Here are the facts and the corporate excerpts from the conference call and the press releases about Epuris with the growing market share in Canada (at 41% today), Absorica, Absorica LD that will keep generating revenue for CPH for many years to come.
And here are some of the growth initiatives for the next couple of years again based on facts: (1) Absorica: "Earlier this year, Sun Pharmaceutical Industries, Cipher’s marketing partner for Absorica, launched Absorica LD capsules in the U.S. for the management of severe nodular acne in patients 12 years of age and older.
In addition to the benefits of Absorica LD will bring to the patient population, the launch triggered an extension of our agreement with Sun Pharmaceuticals, providing us with two additional years of royalties on Sun’s isotretinoin product portfolio. As previously communicated, the royalty rate on Absorica LD will be identical to the royalty on Absorica until December 2021. The extension allows for a reduced royalty rate in subsequent years. "
"And then sort of secondarily to that, I think we’re all obviously focused on timelines when Allergan can launch its own generic Absorica, which I believe is next month, any update on that would be helpful. And then I have a follow-up. Craig Mull: Okay. So the launch of a generic is something that we are watching very closely. We’re trying to get as much information that we can about any potential launch of generic of Absorica. We have not seen it. There has been no entries to-date. We have talked to them about different pricing strategies. We’re preparing in the event of a launch of a generic to be able to come out with an authorized generic and maintain a significant share of that market. So this is a day-to-day thing and we’re certainly in communication with Sun and we’re also doing our own reconnaissance on any potential launch of the generic." (2) Trevyent: "Lastly Trevyent should get approval so that may help a bit." (3) The recent deal with Verity for CPH's hospital products, facts below:
https://www.newswire.ca/news-releases/cipher-pharmaceuticals-enters-into-co-promotion-agreement-with-verity-pharmaceuticals-inc--863868176.html "We are pleased to have finalized our Agreement with Verity as we continue growing the hospital business and providing industry-leading products," said Craig Mull, Interim CEO of Cipher.
"We are confident that working with Verity is the right economic decision for Cipher and is consistent with our strategy of seeking promotional partners for our products. Verity's expertise and proven sales force will allow us to manage our costs efficiently and drive continued profitability within our hospital business," added Mr. Mull.
(4) The tattoo program, facts from the latest CC:
"In our tattoo program, the U.S. patent office issued a Notice of Allowance for the U.S. patent application covering Tattoo dermal compositions (topical, transdermal and intradermal). We have received encouraging results from the proof of concept studies and identified a lead candidate compound. Planning is currently underway for the next focused animal study that will incorporate test parameters that will potentially broaden and reinforce the existing IP portfolio."
(5) Galephar and new product opportunities including Alitretinoin, facts from the latest CC:
"We also continue to work with our development partner, Galephar, on a number of interesting projects, including Alitretinoin, a drug for severe hand eczema for the U.S. market. Cipher and Galephar are working closely and expect to receive feedback on recent submissions to the FDA. Cipher continues to evaluate the market potential for this product. " (6) Moberg and MOB-015 (Nail fungus), facts from the latest CC:
"Our development partner, Moberg, has developed a proprietary formulation that can deliver high concentrations of active drug to the nail that competing products on the market have difficulty in matching. To-date, Moberg has conducted two North American Phase 3 studies. In these studies, the overall cure rates were lower than competing products at 4.5%. However, in contrast to the competing products, the mycological cure rate was 50% in less than 24 weeks while the competing products were quite longer to reach this rate. Moberg is considering conducting additional trials to address the complete cure rate by shortening the treatment period.
Our development partner, Moberg, has developed a proprietary formulation that can deliver a higher concentration of active drug to the nail bed than competing products on the market. To date, Moberg has conducted two Phase III studies for MOB-015 that have met the primary endpoint.
Although the overall cure rates were low, there was a significant antifungal effect, as demonstrated in the secondary endpoints of the studies where the mycological cure was achieved in 84% of patients, which is unprecedented for a topical treatment and even higher than reported for oral treatments.
Cipher is continuing discussions with Moberg on next steps."